Literature DB >> 30173593

Predicting disease progression in cystic fibrosis.

Oded Breuer1,2, Daan Caudri1,2,3, Stephen Stick1,2, Lidija Turkovic1.   

Abstract

INTRODUCTION: Progressive lung disease is the major cause of morbidity and mortality in patients with cystic fibrosis (CF). Methods of correctly predicting the future progression of lung disease in patients with CF are essential for directing aggressive treatment to prevent loss of lung function and end stage respiratory failure. Areas covered: This review addresses predictors of respiratory disease progression in patients with CF. We searched Web of Science and Medline, with no restriction on publication date, with the search terms 'cystic fibrosis' and 'disease progression', 'lung function decline', 'prognosis', 'prediction/predictive', 'prediction/prognostic scores', 'risk factors', 'outcome measures/endpoints/disease surrogate', 'longitudinal/long term', 'statistical model', and 'survival'. Expert commentary: Forced expiratory volume in 1 sec (FEV1) and rate of FEV1 decline, remain the most significant predictors of mortality in patients with CF while CT scores and airway secretion biomarkers are the main predictors of early CF lung disease. Comprehensive scores incorporating clinical, lung function, imaging and laboratory data will become essential in the future for predicting disease progression and for use in clinical trials. Early interventions may delay the progression of structural lung disease.

Entities:  

Keywords:  Chest CT scores; FEV1% predicted; Lung clearance index (LCI)

Mesh:

Substances:

Year:  2018        PMID: 30173593     DOI: 10.1080/17476348.2018.1519400

Source DB:  PubMed          Journal:  Expert Rev Respir Med        ISSN: 1747-6348            Impact factor:   3.772


  11 in total

Review 1.  Targeting of Glycosaminoglycans in Genetic and Inflammatory Airway Disease.

Authors:  Robin Caird; Michael Williamson; Azeez Yusuf; Debananda Gogoi; Michelle Casey; Noel G McElvaney; Emer P Reeves
Journal:  Int J Mol Sci       Date:  2022-06-08       Impact factor: 6.208

2.  Sleep-disordered breathing in cystic fibrosis.

Authors:  Aarti Shakkottai; Samya Z Nasr; Fauziya Hassan; Sanaya Irani; Louise M O'Brien; Ronald D Chervin
Journal:  Sleep Med       Date:  2020-06-05       Impact factor: 3.492

Review 3.  The future of cystic fibrosis care: a global perspective.

Authors:  Scott C Bell; Marcus A Mall; Hector Gutierrez; Milan Macek; Susan Madge; Jane C Davies; Pierre-Régis Burgel; Elizabeth Tullis; Claudio Castaños; Carlo Castellani; Catherine A Byrnes; Fiona Cathcart; Sanjay H Chotirmall; Rebecca Cosgriff; Irmgard Eichler; Isabelle Fajac; Christopher H Goss; Pavel Drevinek; Philip M Farrell; Anna M Gravelle; Trudy Havermans; Nicole Mayer-Hamblett; Nataliya Kashirskaya; Eitan Kerem; Joseph L Mathew; Edward F McKone; Lutz Naehrlich; Samya Z Nasr; Gabriela R Oates; Ciaran O'Neill; Ulrike Pypops; Karen S Raraigh; Steven M Rowe; Kevin W Southern; Sheila Sivam; Anne L Stephenson; Marco Zampoli; Felix Ratjen
Journal:  Lancet Respir Med       Date:  2019-09-27       Impact factor: 30.700

4.  Prognosis-Based Early Intervention Strategies to Resolve Exacerbation and Progressive Lung Function Decline in Cystic Fibrosis.

Authors:  Neeraj Vij
Journal:  J Pers Med       Date:  2021-02-03

5.  A screening tool to identify risk for bronchiectasis progression in children with cystic fibrosis.

Authors:  Daan Caudri; Lidija Turkovic; Nicholas H de Klerk; Tim Rosenow; Conor P Murray; Ewout W Steyerberg; Sarath C Ranganathan; Peter Sly; Stephen M Stick; Oded Breuer
Journal:  Pediatr Pulmonol       Date:  2021-10-12

6.  Lung function over the life course of paediatric and adult patients with cystic fibrosis from a large multi-centre registry.

Authors:  Arul Earnest; Farhad Salimi; Claire E Wainwright; Scott C Bell; Rasa Ruseckaite; Tom Ranger; Tom Kotsimbos; Susannah Ahern
Journal:  Sci Rep       Date:  2020-10-15       Impact factor: 4.379

Review 7.  Toward the Establishment of New Clinical Endpoints for Cystic Fibrosis: The Role of Lung Clearance Index and Cardiopulmonary Exercise Testing.

Authors:  Elpis Hatziagorou; Asterios Kampouras; Vasiliki Avramidou; Ilektra Toulia; Elisavet-Anna Chrysochoou; Maria Galogavrou; Fotios Kirvassilis; John Tsanakas
Journal:  Front Pediatr       Date:  2021-02-25       Impact factor: 3.418

8.  An 8 week open-label interventional multicenter study to explore the lung clearance index as endpoint for clinical trials in cystic fibrosis patients ≥8 years of age, chronically infected with Pseudomonas aeruginosa.

Authors:  Sivagurunathan Sutharsan; Susanne Naehrig; Uwe Mellies; Christian Sieder; Jörg Ziegler
Journal:  BMC Pulm Med       Date:  2020-06-12       Impact factor: 3.317

9.  Bacterial Surface Detachment during Nebulization with Contaminated Reusable Home Nebulizers.

Authors:  Jamie C Harris; Melanie S Collins; Pamela H Huang; Craig M Schramm; Thomas Nero; Jing Yan; Thomas S Murray
Journal:  Microbiol Spectr       Date:  2022-02-02

10.  Clinical course and risk factors for severe COVID-19 among Italian patients with cystic fibrosis: a study within the Italian Cystic Fibrosis Society.

Authors:  Carla Colombo; Marco Cipolli; Valeria Daccò; Paola Medino; Federico Alghisi; Maura Ambroni; Raffaele Badolato; Fiorella Battistini; Elisabetta Bignamini; Rosaria Casciaro; Fabiana Ciciriello; Mirella Collura; Isabella Comello; Michela Francalanci; Francesca Ficili; Anna Folino; Salvatore Leonardi; Giuseppina Leonetti; Maria Cristina Lucanto; Francesca Lucca; Massimo Maschio; Valeria Mencarini; Barbara Messore; Giovanna Pisi; Giovanna Pizzamiglio; Piercarlo Poli; Valeria Raia; Luca Riberi; Mirco Ros; Novella Rotolo; Angela Sepe; Giovanni Taccetti; Pamela Vitullo; Gianfranco Alicandro
Journal:  Infection       Date:  2021-12-07       Impact factor: 7.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.